I have no idea which patients have been resected. I think the overall median survival data is 16 months which is greater than current best practice of 9-11 months. And as some of the patients continue to live the median survival rate will continue to increase as well. So, in effect the OS data can show close to double the same average for current best practice with chemo only. In other words it wouldn’t surprise me that OS data will now show closer to 18 months, closer to double the average OS data for chemo only. IMO this is important data as it demonstrates significant clinical benefit of the Oncosil device.
OSL Price at posting:
6.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)